C., & Adamo, M
90 A recent clinical trial assessing the histological benefits of tirzepatide for MASH reported that tirzepatide 5 mg achieved at least one-stage improvement in fibrosis for 55% of patients without worsening MASH, and 43.6% of patients experienced MASH resolution with no worsening fibrosis
b Hanson et al., c Dooley et al., d Lohman and Remington, e Schwarzlnder et al., f Dihydrolipoic acid (DHLA, reduced form), Lipoic acid (LA, oxidized form)
doi: 10.1038/srep35539
Liver Support 60 Caps FA So Good
has been a supported speaker or consultant for AstraZeneca, Boehringer Ingelheim, Kallyope, Merck, Novo Nordisk and Pfizer, as well as receives grant support for preclinical studies from Amgen, Zealand Pharma and Eli Lilly